Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events

Atherosclerosis

Volumn 147, Issue SUPPL. 1, 1999, Pages

  Arntz, Hans Richard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

CARE study; L CAD study; LIPID study; PAIS study; Pravastatin; RECIFE study; Secondary CHD prevention; Simvastatin

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; STATINE DERIVATIVE;

ARTERY ENDOTHELIUM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; PRIORITY JOURNAL; SECONDARY PREVENTION;

ANGINA PECTORIS; ANTICHOLESTEREMIC AGENTS; CORONARY ARTERIOSCLEROSIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MYOCARDIAL INFARCTION; PRAVASTATIN; RECURRENCE;

EID: 0032884058     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00251-8     Document Type: Conference Paper

References (25)

1. Neaton J.D., Blackburn H., Jacobs D. et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch. Intern. Med. 152:1992;1490-1500.
2. Smith G.D., Shipley M.J., Marmot M.G., Rose G. Plasma cholesterol and mortality. The Whitehall Study. J. Am. Med. Assoc. 267:1992;70-76.
3. Chen Z., Peto R., Collins R. et al. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations. BMJ. 303:1991;276-282.
4. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33:1992;1569-1582.
5. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
6. Sacks F.M., Pfeffer M.A., Moyle L.A. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Eng. J. Med. 335:1996;1001-1009.
7. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med 1998;339:1349-57.
8. Shepherd J., Cobbe S.M., Ford I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N. Eng. J. Med. 333:1995;1301-1307.
9. The West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol 1997;79:756-62.
10. Wood D., De Backer G., Faergeman O. et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies of Coronary Prevention. Eur. Heart J. 19:1998;1434-1503.
11. Adamson H., Jacobs A., Warrington S. Reference ranges for laboratory safety tests in young healthy subjects. Int. J. Pharm. Med. 12:1998;293-296.
12. Mainard F., Ozanne P., Madec Y. Variations in lipoproteins, hormones and blood glucose during the early acute phase of myocardial infarction. Atherosclerosis. 69:1988;225-231.
13. Mbewu A.D., Durrington P.N., Bulleid S., Mackness M.I. The immediate effect of streptokinase on serum lipoprotein(a) concentration and the effect of myocardial infarction on serum lipoprotein(a), apolipoproteins A1 and B, lipids and C-reactive protein. Atherosclerosis. 103:1993;65-71.
14. Ryder R.E., Hayes T.M., Mulligan I.P. et al. How soon after myocardial infarction should plasma lipid values be assessed? BMJ. 289:1984;1651-1653.
15. Gore J.M., Goldberg R.J., Matsumoto A.S. et al. Validity of serum total cholesterol level obtained within 24 hours of acute myocardial infarction. Am. J. Cardiol. 54:1984;722-725.
16. Todd I.C., Wosornu D., Stewart I., Wild T. Cardiac rehabilitation following myocardial infarction. A practical approach. Sports Med. 14:1992;243-259.
17. The West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J 1997;18:1718-24.
18. Vaughan C.J., Murphy M.B., Buckley B.M. Statins do more than just lower cholesterol. Lancet. 348:1996;1079-1082.
19. Rosenson R.S., Tangney C.C. Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. J. Am. Med. Assoc. 279:1998;1643-1650.
20. Weissberg P. Mechanisms modifying atherosclerotic disease - from lipids to vascular biology. Atherosclerosis 1999; 147 Suppl. 1: S3-S10.
21. Crisby M, Nilsson J. Effect of pravastatin on carotid-plaque composition in high-grade symptomatic carotid artery stenosis. The Lancet Conference. The Challenge of Stroke, October, 1998.
22. Kesteloot H., Claeys G., Blanckaert N., Lesaffre E. Time course of serum lipids and apolipoproteins after acute myocardial infarction: modification by pravastatin. Acta Cardiol. 52:1997;107-116.
23. den Hartoq F.R., Verheugt F.W.A. Early HMG-CoA reductase inhibition in acute coronary syndromes: preliminary data of the Pravastatin in Acute Ischaemic Syndromes study (PAIS) (abstract). Eur. Heart J. 19(Suppl):1998;P2802.
24. Dupuis J., Tardif J.-C., Théroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes (abstract). J. Am. Coll. Cardiol. 31(Suppl A):1998;891-896.
25. Arntz, HR, Wunderlich W, Schnitzer L. The decisive importance of cholesterol lowering therapy for coronary lesions and clinical course immediately after an acute coronary event: short and long term results of a controlled study. Circulation 1998: 98 Suppl. 1: I-45, 222.